Mylan demands payback from Strides on plants targeted by FDA

Tracy Staton

recently got hammered by the FDA in a warning letter for three plants that it acquired as part of its $ 1.75 billion acquisition of the sterile injectables business of what was then Arcolabs.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS